Amiloidózis: vizsgálatok itt: Kanada
11 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleMAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- Where
- Calgary, Montreal, Toronto, Vancouver
- Életkor
- 18 év to 90 év
- People
- 1200 worldwide
- Run by
- Intellia Therapeutics
See details and how to joinNCT06128629 · EU 2023-507220-23-00 - 3. fázisTaking peopleCLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
- Where
- Calgary, Greater Sudbury, Halifax, Hamilton, Kitchener, London, Mississauga, Ottawa, Québec, Rimouski, Scarborough Village, Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 1280 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07207811 - 3. fázisTaking peopleTRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Where
- Calgary, London, Toronto, Vancouver
- Életkor
- 18 év to 85 év
- People
- 1750 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00 - 3. fázisTaking peopleTRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
- Where
- Vancouver
- Életkor
- 18 év to 85 év
- People
- 125 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07223203 · EU 2025-522544-40-00 - No phaseTaking peopleNon-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- Where
- Halifax, London, Montreal, Rimouski, Toronto, Vancouver
- Életkor
- 18 év to 130 év
- People
- 1850 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06465810 - No phaseTaking peopleLong-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations
- Where
- Vancouver
- Életkor
- 18 év and over
- People
- 320 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07654855 - No phaseTaking peopleOverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
- Where
- Calgary
- People
- 52 121 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06355934 - 3. fázisNot yet taking people in KanadaAn Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
- Where
- Calgary, Chicoutimi, London, Montr Al, Rimouski, Winnipeg
- People
- 1180 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00 - 3. fázisTaking peopleAcoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Where
- Calgary, Toronto, Vancouver
- Életkor
- 18 év to 75 év
- People
- 587 worldwide
- Run by
- Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895 · EU 2024-513547-82-00 - 1/2. fázisTaking peopleA Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
- Where
- Calgary, Toronto
- Életkor
- 18 év and over
- People
- 91 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07081646 - 3. fázisCsak meghívásosAn Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
- Where
- Calgary, London, Montreal, Rimouski, Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 1400 worldwide
- Run by
- Ionis Pharmaceuticals, Inc.
See details and how to joinNCT05667493